Adamax

Adamax is marketed in the research-peptide world as a nootropic, claimed to sharpen focus and mental clarity, the same claims sold for Semax, the Russian peptide it's built from. Vendors describe it as Semax with two add-ons, an acetyl cap and a bulky 'adamantane' group, meant to help it last longer and reach the brain more easily. It isn't approved as a medicine anywhere, and no published study has ever tested a peptide called Adamax, so nearly every claim about it is carried over from Semax rather than proven on Adamax itself.

Adamax is marketed as a Semax-like nootropic — described as raising BDNF (a nerve-growth protein) and interacting with melanocortin receptors — but there is no primary research on it: a medical-literature search finds only an unrelated computer-science paper. Vendor descriptions are marketing rather than measured results, and different sellers describe the sequence differently, so every efficacy and dosing claim should be treated as unverified.

Not FDA-approved for any indication and never submitted to FDA; sold only as a research chemical ("not for human consumption"). Not registered as a pharmaceutical drug in any jurisdiction (unlike Semax, which is registered in Russia). Not a DEA-controlled substance — no entry in the DEA *Lists of Scheduling Actions, Controlled Substances, Regulated Chemicals* (August 2026 revision), checked 2026-09-08.[⁶] Prohibited in drug-tested sport at all times, under WADA S0. Adamax is not named on the 2026 WADA Prohibited List (verified by text search, 2026-09-08), but not-named is not permitted: S0 catches any substance with no current approval for human therapeutic use from any governmental health authority, which describes Adamax. A later section does not displace S0 either — the only corticotropic entry, S2.2.2, names corticorelin and tetracosactide, both of which act on the adrenal axis, and an ACTH(4-10) fragment of the Semax family does not. Competitors should treat Adamax as prohibited and consult their National Anti-Doping Organization. Available only through research-peptide suppliers; identity and purity are not independently established. Distinct from Cortagen (Ala-Glu-Asp-Pro / AEDP) — do not confuse the two.

Adamax is not FDA-approved and has never been studied in a published clinical trial; its safety and even its exact composition are not independently established, and sellers describe it inconsistently. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

⚠️ For research and educational purposes only. Adamax is not approved by the FDA or any regulator as a drug for any indication and is sold only as a research chemical. Information in this entry is informational, not medical advice. Always confirm dose calculations with the in-app calculator and consult appropriate professional guidance before any protocol decisions.

⚠️ No primary literature exists for a peptide named "Adamax." According to PubMed, a search for "Adamax peptide" returns exactly one indexed record — and it is an unrelated machine-learning paper describing the "Adamax optimizer" algorithm for blood-glucose forecasting, not a study of any peptide.[¹] There are no clinical trials, no human data, and no peer-reviewed preclinical studies of Adamax itself. Everything below that is specific to "Adamax" — its sequence, its modifications, its dosing, its effects — comes from research-vendor marketing pages, which describe the compound inconsistently. Read this entry as documentation of *what Adamax is marketed as*, not as evidence that it works.

⚠️ Adamax is not the same as Cortagen / AEDP. The two are readily confused, and the conflation is worth naming: AEDP is Cortagen — a separate, brain-cortex peptide that has its own [Cortagen entry](./cortagen.md) — and the thymus-tropic Khavinson peptide is Vilon (Lys-Glu), not AEDP. Adamax itself is a Semax-family neuropeptide marketed for cognition, with no thymus/immune positioning and no Khavinson-bioregulator identity.

⚠️ The vendor-claimed identity is a Semax analog — but the details conflict. The most common vendor description is Ac-MEHFPGPAG-NH₂: the Semax backbone (Met-Glu-His-Phe-Pro-Gly-Pro) N-terminally acetylated, extended by Ala-Gly, C-terminally amidated, and carrying an adamantane ("adamantyl") group borrowed from the peptide P21 to improve lipophilicity, enzymatic stability, and blood-brain-barrier penetration.[³] Other sellers describe it more loosely as simply "N-acetyl-Semax," and some conflate it with P21 or with NAP/davunetide. There is no authoritative registry, structural paper, or CAS/PubChem record cross-checked here to lock the sequence, so the sequence, molecular weight, and modifications are all marked. Do not treat the vendor sequence as confirmed.

⚠️ Every mechanism and effect claim below is extrapolated from Semax, not measured on Adamax. The BDNF/TrkB and melanocortin-receptor framing is the mechanism of the *parent* Semax compound.[²] Whether Adamax reproduces, exceeds, or fails to reproduce those effects has never been tested in any published study. See the [Semax entry](./semax.md) for the compound Adamax is derived from.

What the research-peptide market sells as "Adamax." Adamax is a compound offered by research-chemical suppliers as a chemically modified analog of Semax — the Russian ACTH(4-10)-derived heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) used in Russia as a neuroprotective/nootropic medication (see the [Semax entry](./semax.md)). Vendor and marketing pages present Adamax as Semax with two additions intended to improve pharmacokinetics: an N-terminal acetyl cap (to slow aminopeptidase degradation) and a C-terminal adamantane group (a bulky, lipophilic diamondoid cage, the same scaffold used in CNS drugs such as amantadine and memantine, intended to improve enzymatic stability and blood-brain-barrier penetration). The most frequently quoted sequence is Ac-MEHFPGPAG-NH₂, with the adamantane/Ala-Gly-amide modifications described as adapted from the peptide P21 (see [P21 entry](./p021.md)).[³] The name itself is a portmanteau of *adamantyl* and *Semax*.

The evidence problem — read this before anything else. There is no peer-reviewed primary literature on a peptide named "Adamax." According to PubMed, the sole indexed record matching "Adamax peptide" is an unrelated machine-learning paper about the "Adamax optimizer" algorithm (a gradient-descent method) applied to blood-glucose forecasting — not a peptide study at all.[¹] A search for an "adamantyl Semax analog" returns zero results. This means that, unlike Semax (which has a real, if Russian-skewed, published mechanism literature), Adamax has essentially no independent scientific record. Its identity, sequence, modifications, dosing, and claimed effects are documented only on research-vendor product pages and secondary "peptide encyclopedia" sites, and those sources disagree with one another — some describe Ac-MEHFPGPAG-NH₂, others equate Adamax with plain "N-acetyl-Semax," and others conflate it with P21 or unrelated neuroprotective peptides. Because of that, this entry deliberately does not assert a confirmed sequence, molecular weight, or mechanism; all such fields carry.

Claimed mechanism (inherited from Semax, not tested on Adamax). Vendors describe Adamax as acting through the same pathways attributed to Semax: upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, plus interaction with melanocortin receptors (MC1R/MC3R/MC4R/MC5R) given the ACTH-fragment origin. The BDNF/TrkB mechanism is genuinely documented for Semax in the peer-reviewed literature — e.g., a single intranasal dose of Semax increases hippocampal BDNF and TrkB expression in rats and improves conditioned avoidance learning.[²] Whether Adamax shares this mechanism, at what potency, or with what duration, has never been measured in any published study. Treat the mechanism section as "what the parent compound does," carried over by vendors on structural analogy.

Distinction from Cortagen and the Khavinson bioregulators. Adamax is sometimes conflated with the Khavinson tetrapeptide AEDP (Ala-Glu-Asp-Pro) and given a thymus/immune indication. That conflation fails on three counts: (1) AEDP is Cortagen, a brain-cortex peptide with its own [entry](./cortagen.md); (2) the thymus-associated Khavinson peptide is Vilon (Lys-Glu), not AEDP; and (3) Adamax is a Semax-family cognitive peptide, not an immune bioregulator. Adamax is not a Khavinson bioregulator and has no established thymus, immune, or T-cell activity.

Regulatory status (US). Adamax is not FDA-approved for any indication and has never been submitted to FDA. It is sold only as a research chemical labeled "not for human consumption." It is not DEA-scheduled. Unlike Semax (registered as a medication in Russia), Adamax is not registered as a pharmaceutical drug in any jurisdiction.

Regulatory status (sport — WADA). Prohibited at all times under S0.

Adamax is not named on the 2026 WADA Prohibited List. A text search of the canonical list returned zero matches for "Adamax", "Semax", "ACTH", "ACTH(4-10)", "melanocortin" and "n-Acetyl" (checked 2026-09-08).[⁵]

That is a naming result, not a permission. WADA S0 (Non-Approved Substances) reads, verbatim:

> Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

Adamax holds no approval for human therapeutic use from any governmental health authority anywhere, so S0 captures it by default and it is prohibited at all times, in and out of competition.

Why a later section does not displace S0 — stated explicitly so it is not re-argued. S0 applies only to a substance "not addressed by any of the subsequent sections". The candidate section is S2.2.2, Corticotrophins and their releasing factors, whose named examples are corticorelin and tetracosactide. Both are corticotropic: they act on the hypothalamic-pituitary-adrenal axis to drive cortisol release. Adamax is an ACTH(4-10) fragment of the Semax family, and that fragment is the melanocortin/neurotropic portion — it lacks the C-terminal region responsible for adrenal steroidogenic activity, which is why the Semax family is studied for neurological rather than corticotropic effect. It is therefore not addressed by S2.2.2, and S0 applies.

Note the direction of that reasoning: falling outside S2.2.2 makes Adamax more clearly prohibited, not less, because S0 is the residual category. Competitors should treat Adamax as prohibited at all times and consult their National Anti-Doping Organization.

*Contrast with Semax itself, which is a registered medicine in Russia: that approval is exactly what takes Semax out of S0's reach. Adamax has no such approval anywhere, so the two are not interchangeable on this point.*

Commonly reported

• Mild nasal irritation or rhinorrhea (intranasal use)
• Injection-site reactions (subcutaneous use)
• Headache
• Overstimulation, jitteriness, or disrupted sleep if dosed late in the day (Semax's dopaminergic activation)
• No human safety data of any kind, at any dose, for any duration.
• The claimed CNS-penetration modifications (adamantyl group) are exactly the features most likely to change safety relative to Semax — and none of that has been studied.

Serious

• Severe allergic/hypersensitivity reaction (rash, swelling, difficulty breathing)
• Severe or infected injection-site reaction
• Any unexpected neurological or psychiatric change

Pregnancy and lactation: no data; default to contraindicated.

Pediatric use: no data; should not be used in research settings involving anyone under 18.

Active psychiatric or neurological condition under treatment: caution; no interaction or safety data.

Known peptide allergy or hypersensitivity: contraindicated.

Unknown identity/purity: treat any Adamax product as of unverified composition; there is no independent way to confirm what a vial contains.

Regulatory note (US): not FDA-approved for any indication; sold only as a research chemical; not DEA-scheduled.

Regulatory note (sport): prohibited at all times in drug-tested sport under WADA S0. Not named on the 2026 List, but S0 catches any substance with no approval for human therapeutic use anywhere, and S2.2.2 (corticotrophins) does not reach an ACTH(4-10) Semax-family fragment. Consult your National Anti-Doping Organization before any competitive use.[⁵]

Semax

A Russian synthetic peptide (Met-Glu-His-Phe-Pro-Gly-Pro) based on a fragment of the hormone ACTH, used in Russia as a neuroprotective and nootropic medication. Adamax is marketed as a modified version of it.

Nootropic

A substance used with the goal of supporting cognition, focus, or memory. The term makes no claim that a given compound is proven to work.

Adamantane (adamantyl)

A bulky, fat-loving cage-shaped molecule (the same scaffold used in drugs like memantine) sometimes attached to peptides to help them resist breakdown and cross into the brain.

Research peptide

A compound sold for laboratory research only, not approved or tested as a medicine, with no guarantee of identity, purity, or safety.

1. Sawant PM, Ghongade RB. (2026). Diabetes Management Through Glucose Dynamics Analysis Network: A Novel Approach for Accurate Blood Glucose Level Forecasting. Diabetes, Obesity & Metabolism, 28(8):7352-7366.(PMID 42236259)
2. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1):54-60.(PMID 16996037)
3. In-library cross-references: Semax (the parent compound), Cortagen (AEDP — the compound Adamax is most often conflated with), and P21 / P021 (the source of the adamantyl/amide modifications vendors attribute to Adamax). These are internal VialWise entries provided for orientation, not external evidence for Adamax.
4. Vendor / marketing sources (not peer-reviewed; descriptions conflict; used only to document what Adamax is marketed as, not that it works). Representative pages consulted 2026-07-18 include medsbase.com ("n-Acetyl-Semax" framing), exploring-peptides.com and edgepeptides.com ("Semax vs. Adamax" comparisons), semaxpolska.com, and BOC Sciences' catalog listing (aapep.bocsci.com). These sources variously describe Adamax as Ac-MEHFPGPAG-NH₂, as plain N-acetyl-Semax, or as a P21-modified Semax — the inconsistency is itself the finding. — no authoritative registry (CAS/PubChem/ChEMBL) record was cross-checked to confirm the sequence, and none should be assumed.
5. World Anti-Doping Agency. World Anti-Doping Code International Standard — Prohibited List 2026 (effective 1 January 2026). Canonical PDF: wada-ama.org, archived in this repo at `docs/legal/wada-2026-prohibited-list.pdf` (382,029 bytes) with a text extraction alongside it. Cited for a negative naming result and for the verbatim S0 clause. Text search on 2026-09-08 returned zero matches for "Adamax", "Semax", "ACTH", "ACTH(4-10)", "melanocortin", "n-Acetyl" and "adrenocorticotroph"; "Corticotroph" returns only the S2.2.2 heading, whose named examples are corticorelin and tetracosactide. ⚠️ Methodology note. A live fetch of the WADA url on 2026-09-08 returned 0 bytes (blocked), so the canonical archive could not be checksum-matched against the publisher on that date. Corroboration was obtained instead from an independent transposition of the same instrument into national law: the Austrian Federal Law Gazette, BGBl III Nr 219/2025, attachment at rdb.manz.at. The S0 text and the S2.2.2 named examples are identical in both copies, and the same zero-hit results reproduce in the Austrian copy. Two independent copies from different jurisdictions agreeing is a stronger check than a checksum against one publisher.
6. U.S. Department of Justice, Drug Enforcement Administration, Diversion Control Division. Lists of Scheduling Actions, Controlled Substances, Regulated Chemicals ("the DEA Orange Book"), August 2026 revision, 139 pp. deadiversion.usdoj.gov. Cited for a negative scheduling result, which requires naming the full list and the date it was checked: a text search of the complete document on 2026-09-08 returned zero matches for "Adamax", "Semax" and "ACTH". The nine hits for "adamantyl" are synthetic cannabinoids (APINACA and related indazole-carboxamides), an unrelated compound class. Extraction was validated with a positive control before the negative was trusted — Testosterone, Fentanyl, Ketamine and Oxycodone all resolve in the extracted text.

• Cerebrolysin — same mechanism class
• DSIP — same mechanism class
• Oxytocin — same mechanism class
• P021 — same mechanism class
• PE-22-28 — same mechanism class
• Selank — same mechanism class